United States Biotechnology & Medical Research

Adicet Bio Inc (ACET)

Track

In the last 90 days, Adicet Bio Inc. saw significant insider selling, with a net value of -$674,847.06. Total sell transactions amounted to $1,866,816.37, while no buy transactions were recorded from insiders during this period. The stock has seen a 27.7% price increase over the past 90 days.
Stock chart
Ticker: ACET Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
OrbiMed Genesis Master Fund, L.P.
Shareholder
1 sale — total 514,168 USD
Proposed sale 9 Apr 2026
Value US$1,547,564.80 | Price 434.53 | Shares 47,831
Sale 8 Apr 2026
Value US$4,118,315.80 | Price 179.07 | Shares 69,918
Sale 8 Apr 2026
Value US$4,759,169.64 | Price 26.59 | Shares 7,692
Proposed sale 8 Apr 2026
Value US$264,724.80 | Price 6.55 | Shares 40,416
Sale 7 Apr 2026
Value US$15,312.00 | Price 6.38 | Shares 2,400
Sale 7 Apr 2026
Value US$191,453.07 | Price 6.53 | Shares 29,319
Proposed sale 7 Apr 2026
Value US$413,076.06 | Price 6.43 | Shares 64,242
Buy 20 Feb 2026
Value US$543,439.77 | Price 7.27 | Shares 74,751
Buy 19 Feb 2026
Value US$535,472.28 | Price 7.21 | Shares 74,268
Buy 18 Feb 2026
Value US$525,022.08 | Price 7.04 | Shares 74,577
Buy 8 Oct 2025
Value US$3,500,000.00 | Price 1.00 | Shares 3,500,000
Buy 8 Oct 2025
Value US$1,500,000.00 | Price 1.00 | Shares 1,500,000
Sale 5 Jun 2024
Value US$8,437.00 | Price 1.43 | Shares 5,900
Proposed sale 5 Jun 2024
Value US$8,437.00 | Price 1.43 | Shares 5,900
Buy 25 Jan 2024
Value US$2,500,080.00 | Price 2.40 | Shares 1,041,700
Buy 25 Jan 2024
Value US$581,280.00 | Price 2.40 | Shares 242,200
Buy 25 Jan 2024
Value US$4,418,640.00 | Price 2.40 | Shares 1,841,100
Buy 25 Jan 2024
Value US$2,500,080.00 | Price 2.40 | Shares 1,041,700
Buy 25 Jan 2024
Value US$581,280.00 | Price 2.40 | Shares 242,200
Buy 25 Jan 2024
Value US$4,418,640.00 | Price 2.40 | Shares 1,841,100
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-09 2026-04-09 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
47,831
434.53
US$1,547,565 		47,831 434.53 US$1,547,565
2026-04-09 2026-04-08 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
69,918 -16.9%
179.07
US$4,118,316 		69,918 -16.9% 179.07 US$4,118,316
2026-04-09 2026-04-08 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
7,692 -7.1%
26.59
US$4,759,170 		7,692 -7.1% 26.59 US$4,759,170
2026-04-08 2026-04-08 PrS Proposed sale
OrbiMed Israel Partners II, L.P.

Shareholder
40,416
6.55
US$264,725 		40,416 6.55 US$264,725
2026-04-09 2026-04-07 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
2,400 -6.9%
6.38
US$15,312 		2,400 -6.9% 6.38 US$15,312
2026-04-09 2026-04-07 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
29,319 -45.6%
6.53
US$191,453 		29,319 -45.6% 6.53 US$191,453
2026-04-07 2026-04-07 PrS Proposed sale
3.3
OrbiMed Israel Partners Limited Partnership

Shareholder
64,242
6.43
US$413,076 		64,242 6.43 US$413,076
2026-04-13 2026-02-20 B Purchase
3.0
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
74,751 +6.7%
7.27
US$543,440 		74,751 +6.7% 7.27 US$543,440
2026-04-13 2026-02-19 B Purchase
3.0
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
74,268 +7.2%
7.21
US$535,472 		74,268 +7.2% 7.21 US$535,472
2026-04-13 2026-02-18 B Purchase
3.0
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
74,577 +7.8%
7.04
US$525,022 		74,577 +7.8% 7.04 US$525,022
2025-10-10 2025-10-08 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
3,500,000 +353.4%
1.00
US$3,500,000 		3,500,000 +353.4% 1.00 US$3,500,000
2025-10-10 2025-10-08 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
1,500,000 +19.9%
1.00
US$1,500,000 		1,500,000 +19.9% 1.00 US$1,500,000
2024-06-07 2024-06-05 S Sale
3.9
Kauffman Michael
Non-Executive Director
5,900 -50.0%
1.43
US$8,437 		5,900 -50.0% 1.43 US$8,437
2024-06-05 2024-06-05 PrS Proposed sale
3.9
Kauffman Michael

Director

Non-Executive Director
5,900
1.43
US$8,437 		5,900 1.43 US$8,437
2024-01-26 2024-01-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,041,700 +486.1%
2.40
US$2,500,080 		1,041,700 +486.1% 2.40 US$2,500,080
2024-01-26 2024-01-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
242,200 +32.4%
2.40
US$581,280 		242,200 +32.4% 2.40 US$581,280
2024-01-26 2024-01-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,841,100 +32.4%
2.40
US$4,418,640 		1,841,100 +32.4% 2.40 US$4,418,640
2024-01-26 2024-01-25 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
1,041,700 +486.1%
2.40
US$2,500,080 		1,041,700 +486.1% 2.40 US$2,500,080
2024-01-26 2024-01-25 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
242,200 +32.4%
2.40
US$581,280 		242,200 +32.4% 2.40 US$581,280
2024-01-26 2024-01-25 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
1,841,100 +32.4%
2.40
US$4,418,640 		1,841,100 +32.4% 2.40 US$4,418,640
Explore more

More insider trading research around Adicet Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America